Abstrakt
Immunization in patients with inflammatory bowel disease (IBC) has certain specificities associated with etiopathogenesis and treatment modalities of the underlying disease.
Modern principles of IBC treatment are characterized by the frequent application of immunomodulatory therapy, which is most often introduced in early stages of treatment, which is one of the main reasons for the strong predisposition of patients with IBC for the development of infection. Vaccination of patients with IBC is necessary in order to reduce infectious complications, especially those that could be prevented by vaccination. It is therefore very important to establish recommendations on the basis of which the immunization of IBC patients would become an integral part of their treatment. The planning and implementation of vaccination in patients with IBC depend on the assessment of the immune response status of each patient at a given moment. This review work presents an overview of the current views on the time of administration of vaccines in patients with IBC, the type of vaccine that can be applied as well as their effect on the course of the disease, the complications and outcome of the treatment. Also, the results of studies that examined the efficacy and safety of vaccines for influenza, varicella zoster, pneumococcal infections, human papillomavirus, hepatitis B and C viruses in IBC patients
Introduction
The planning and implementation of immunization in patients with inflammatory bowel disease (IBC) is a just and necessary step in the treatment and monitoring of the underlying disease, especially in the preparation of a patient for the introduction and application of immunosuppressive therapy.
This opinion is the result of the following findings: the majority of patients with IBC will be treated with immunosuppressive therapy during the illness; a large number of IBC patients are immunocompromised due to the nature and the course of the underlying disease; vaccination is the only form of prevention in certain infectious diseases that can complicate the condition of patients with IBC. The possible more favourable relationship between the cost of treatment of infectious complications and the resulting hospitalization and the costs of vaccination of these patients should not be neglected either.
The immunization of patients with IBC has certain specificities due to the fact that the immune system and the immune response of the patients have been altered under the influence of etiopathogenesis, clinical course characteristics and the treatment of the underlying disease. Due to all this, adequate vaccination planning is needed -the time of vaccine use, type of vaccine, as well as knowledge of safe and effective application, possible interactions with immunosuppressive drugs and the effect of immunization on the immune response.
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In routine clinical practice, special attention is rarely given to immunization data and its implementation in patients with IBC. Namely, the implication of compulsory vaccinations, which have been conducted in most patients and prior to the diagnosis of IBC, separates the clinician from the idea of the necessity of using vaccines during the treatment of these patients. It is therefore very important to define ways of vaccination of patients with IBC, establish recommendations on the basis of which the immunization of IBC patients will become an integral part of their treatment and an important segment in the prevention of infectious complications of these patients.
Predisposition for the development of complications from infectious diseases of ibc patients
Infections that complicate IBC are on the rise. They are the basis of the highest percentage of complications and the need for hospital treatment of these patients. Among them, opportunistic infections, but also infectious diseases that can be prevented by immunization, are particularly important.
Opportunistic infections are defined as serious, usually progressive, infections caused by microorganisms that have limited pathogenic or even non-pathogenic capacity in people with uncompromised immune system. The same microorganisms can cause severe illnesses in the conditions of the predisposing effect of another associated disease or its treatment (1) .
Patients who are immunocompromised have altered, cellular and / or humoral immunity, which increases the risk of opportunistic and infections in general. In patients with IBC, gene mutations for molecules that play an important role in innate immunity have been described, such as receptors for molecular patterns of pathogens and damaged cells (NOD2) or cytokine receptors (IL23R). These mutations are responsible for the changed functional capacity of innate immunity (2, 3) . Also, in patients with IBC, the activity of the acquired (adaptive) immunity cells is also changed. In Crohn's disease, for example, there is a description of an increased activity of Th1 subpopulation of helper lymphocytes (CD4+ T lymphocytes) manifested by increased production of interferon gamma (INF-γ), as well as increased production of cytokines IL-12 and IL-18 by macrophages of mucosa. In contrast to Crohn's disease, in ulcerative colitis, there is primarily an over-response of Th2 subpopulation of helper lymphocytes characterized by increased production of cytokines 6 IL-13 and IL-5. Also, T lymphocytes of patients with ulcerative colitis have a slower cell cycle and are more susceptible to the programmed cell death (apoptosis) compared to control cells (4) . Bearing in mind all the above findings, it is clear that the intestinal lesion in IBC patients is completely under the influence of different "branches" of the immune system.
Despite the deficiencies described in the function of innate immunity and the changed immune function of the cells of the acquired immunity, not all patients with IBC can be considered immunocompromised (5) . Although there is no clear definition of the immunocompromised condition in the IBC, IBC patients are considered immunocompromised if treated with: corticosteroids for two weeks and longer or repeated within three months, with azathioprine (or 6 mercaptopurine), methotrexate, anti-TNF agents as well as patients with high protein-caloric malnutrition. Application of the combination of immunosuppressants in therapy thus modulates the immune system at multiple levels.
Other risk factors for the development of infections, which also intensify the degree of immunosuppression, are malnutrition, surgical interventions, elderly age, co-morbidity, leukopenia within the immunosuppressant application (6).
The occurrence of opportunistic infections is a problem for clinicians. These infections are often more difficult to recognize and diagnose, are associated with high morbidity and mortality because they are potentially serious and less responsive to effective treatment. 
Vaccination
Vaccines are used to achieve a qualitatively and quantitatively appropriate (adequate)
immune response from a recipient that ensures the usefulness of the applied protection. The time of immunization should be such as to provide a balance between the desire to achieve an optimal immune response and the practical need to achieve protection against illness.
The principles of childhood immunization are based on the above. Table 3 . 
Calendar of compulsory vaccinations in

HB -hepatitis B vaccine, contains purified HBsAg; DTP -diphtheria, pertussis and tetanus vaccine, contains diphtheria toxoid, tetanus and inactivated corpuscle B.pertusis; DTadult vaccine, contains diphtheria toxoid and tetanus; MMR -vaccine against measles, mumps and rubella, contains live, attenuated viruses; OPV -poliomyelitis vaccine, contains live, attenuated, 2 types of polio virus; Hib -conjugated vaccine against
Hemophilus influenza type B.
* children who have not been vaccinated by 12 years of age with three doses of vaccine by the scheme of 0, 1, 6 months The calendar also includes the use of a tetanus vaccine (toxoid) that is applied after 30 years of age, every ten years, as well as the use of hepatitis B immunoglobulins (applied in new-born babies of mothers who are HBsAg positive).
Since most IBC patients were vaccinated prior to diagnosis of IBC, when their immune response was not changed due to illness, and according to the mandatory vaccination plan (Table 3) , the specific effect of administered vaccines in patients with IBC does not differ significantly from their effect in non-IBC population. Therefore, although no precise data are available, it is considered that the incidence of the disease against which early immunization was carried out (diphtheria, pertussis, polio, measles, rubeola, tetanus) in the IBC population is negligible. Recommendations for the immunization of patients with IBC (immediately after diagnosis of IBC) are based on the assumption that compulsory vaccines have been previously used, which requires adequate evidence. shown that these patients create an adequate humoral immune response (specific antibodies have been detected). Also, these patients did not exhibit an increase in the activity of the underlying disease as a result of the response of their immune system to the use of vaccines (10, 15, 16, 17, 18) .
Vaccines can be classified into several categories, depending on the characteristics (forms) of the antigens used for their making. They may contain live (attenuated, avirulent) infectious agents (live vaccines) or may be dead vaccines containing inactivated infectious agents of preserved immunogenicity. The immune system recognizes and responds to antigens by activating B lymphocytes (antibody production) and activating T lymphocytes.
From activated T and B lymphocytes, in the process of developing the immune response to the pathogen, memory lymphocytes are created with mechanisms of even faster response in each future exposure to a given pathogen. By measuring the level of production of a specific antibody after immunization, as well as by comparing the antibody level before and after immunization, it is possible to estimate the degree of immune response or the immunogenicity of the applied vaccine.
The immunogenicity of the vaccine (potential to produce an adequate immune response)
can be determined in several ways, and is usually estimated based on the titre of the antibodies produced. Titre of antibodies is determined before immunization and at a certain time interval after vaccination (usually four weeks after immunization). The process of seroconversion involves the formation of a specific antibody titre in seronegative persons (who did not have a measurable antibody titre prior to vaccination), which makes them seropositive. In the seroconversion process, a minimum titre of an anti-infection antibody
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(wild type) is required, and the achievement of said level or greater titre defines the socalled seroprotection -the expected protection (4).
Time of vaccine administration
In conditions of immunosuppression, and therefore in patients with IBC, the use of liveattenuated vaccines is contraindicated, since the entry of a causative agent in the condition of a compromised immune system can lead to the occurrence of infectious disease. As part of the above, it is recommended that the appropriate vaccines be administered within 3 weeks of starting of the immunosuppressive therapy, and the possible application, if the treatment with immunosuppressants is in progress, is recommended after 3 months of discontinuation of these drugs.
The specific situation is vaccination of new-borns of mothers who are treated with anti-TNF agents. According to recent recommendations, the first vaccination should be administered from the 6th month of life, since after this period, the anti-TNF antibodies, which the mother received as a therapy, transferred to the child transplanted, have withdrawn from the bloodstream of the child.
Specificity of vaccination of ibc patients
The most important infectious diseases of adult patients with IBC that can be prevented As noted earlier, the application of a live, attenuated influenza vaccine is contraindicated in patients on immunosuppressive therapy. In this group of IBC patients, the use of trivalent influenza vaccine (TIV) is recommended, which is a type of inactivated vaccine. It is administered once a year (usually before the onset of influenza and in accordance with the recommended vaccine administration time). It has been shown that administration of the vaccine has no effect on IBC activity. It has also been confirmed that seroconversion has not been reduced and altered in patients on steroid, methotrexate and anti-TNF agents or dual therapy with these drugs. At the same time, the administration of thiopurine and cyclosporine affects the reduction in the percentage of seroconversion. A routine check of a serological response in these cases is not necessary in view of the above-mentioned existing knowledge (5).
Varicella -zoster virus (vzv)
VZV causes varicella and herpes zoster (after reactivating a latent VZV infection from the dorsal ganglia). Studies have shown that this is the most common herpes-viral infection in
immunocompromised patients with IBC. Immunosuppression increases the incidence of herpes zoster (mainly in patients older than 50 years of age) and the risk of disseminated and complicated forms of illness (pneumonia, meningoencephalitis, haemostasis disorders). Table 6 .
Levels of Immunosuppression Based Upon Strength of Immunosuppressive
Medication(10)
High-Level Immunosuppression
Treatment with glucocorticoids (prednisone >20 mg/day for ≥2 weeks and within 3 months In the case of a VZV infection in the course of immunosuppressive therapy, antiviral drugs (acyclovir) should be used and the immunosuppression should be stopped, especially in more complicated cases (13) and immunosuppressive therapy should be reintroduced after febrile and vesicle regression (14) .
The need for VZV vaccine, as well as all other vaccines, should be assessed individually in each IBC patient, depending on the application of immunosuppressive therapy, dose and duration of treatment, as well as the assessment of the risk-benefit ratio of the above.
Pneumococcal infections
Streptococcus pneumoniae-induced infections cause more deaths than other vaccinepreventable bacterial infections. Risk factors for the emergence of these infections are chronic immunosuppressive therapy (we see patients with IBC within this), chronic illness and older age. Severe, invasive forms of pneumococcal infections -pneumonia and meningitis (with or without bacteraemia) are followed by higher mortality. In patients with IBC who are on immunomodulatory therapy, bacterial pneumonia caused by pneumococcal is one of the most common opportunistic infections.
Vaccination against pneumococcus should be performed in all patients with risk factors (Table 8) .
IBC patients should be administered with pneumococcal vaccine prior to the introduction of immunosuppressive therapy (at least two weeks before). Combined immunosuppressive therapy has been shown to significantly reduce the immunogenic response to this vaccine (in particular the combination of immunomodulators and anti-TNF agents), while monotherapy with immunomodulators (AZA) has no effect on the reduction of immunogenicity.
In the case of an active pneumococcal infection, the use of immunosuppressive therapy should be suspended until the infection is resolved. Any pneumonia in IBC patients should be treated with antibiotics acting on pneumococcus (penicillin, cephalosporins II and III generations) (9, 10) .
Specific situations Human papillomavirus (hpv)
In all patients with IBC, regular gynaecological examinations and screening for cervical cancer should be performed. In particular, this refers to patients receiving immunosuppressive therapy and implies a compulsory prerequisite for the decision to include this therapy. The use of immunomodulatory therapy can condition the reactivation of HPV infection.
Study data indicate an increased percentage of abnormal PAPA findings in patients receiving immunosuppression (table 7) , an increased risk of cervical dysplasia, and a higher number of patients with persistent HPV infection (22) (23) (24) . When it comes to HPV infection, especially infection with high-risk viral types, the best preventive measure is vaccination. The use of 4-valent (containing types 6, 11, 16 and 18)
Gardasil vaccine belonging to the type of inactivated vaccines is recommended. It is effective, safe and provides long-lasting immunity. It is recommended to use in young women of the female sex with IBC (up to 26 years of age), as well as in men of the same age (especially those who practice homosexual relationships). Routine administration in the general population is recommended at the age before starting sexual intercourse (for female sex, from 11 to 14 years of age).
The use of immunomodulatory therapy has no effect on the administration and effectiveness of this vaccine. In the case of a clinically high infection (extensive skin changes or genital warts), discontinuation of immunosuppressive therapy should be considered until the changes are cured.
Hepatitis B and C
The prevalence of infection with Hepatitis B and C viruses in patients with IBC is no different from that in the general population (21) . Vaccination against hepatitis B is carried out by mandatory calendar (after birth, after 1 and 6 months) and efficacy is checked serologically. In case it has not been conducted at the specified age, it is applied at age 12, in three doses (0, 1 and 6 weeks).
In all IBC patients, a serological analysis of HBV antigen (HbsAg) and anti-HBs and antiHBc antibodies is performed. In HBsAg positive patients, the viral DNA concentration is checked using a PCR method. In seronegative patients, vaccination is carried out. In most If the use of antiviral drugs was not effective, in 50% of cases, the reactivation of HB infection was described.
In patients who are HBsAg negative, and HBcAb positive (occult infection) virus reactivation occurs rarely during immunosuppressive therapy (5) . In these patients, virus activity should be monitored for 2-3 months, with DNA virus detection, using the PCR method, and in case of positivity (HBV-DNA detection), antiviral drugs should be applied according to the above protocol. There are no previous case reports of disseminated BCG following vaccination of individuals or infants born to mothers taking anti-TNF therapies. However, it is well recognised that TNF-alpha is crucial to granuloma formation and anti-tuberculous immunity.
Infliximab is an IgG1 antibody that does not cross the placenta in the first trimester, thereby reducing exposure to the foetus during the period of organogenesis. The evidence suggests that the rates of miscarriage, prematurity and congenital malformations in women 23 exposed to infliximab are not different from non-exposed pregnancies However, in the third trimester it readily crosses the placenta, remaining detectable in the infant's serum for up to 7 months after birth.
When possible,infliximab should be stopped in the 3rd trimester. However the decision must be made on case by case basics when active disease could have just a harmful consequence on pregnancy outcome.
If BCG vaccination is accidentaly given to an infant born to a mother on infliximab(avoid until 12th month of life), empirial mycobacterial prophylaxis may reduce the chances of dissemination infection (27) (28) (29) (30) (31) .
Only few studies have assessed effects of vaccination with BCG on subsequent risk of IBD (Leigh 1980 , Gilat 1987 , Baron 2005 . Danish prospective and population-based casecohort study conducted at 47622 participants showed that BCG vaccination do not affect later risk of developing CD and UC (Villumsen 2013 ). Other vaccines that can be safely administered are the vaccine against Japanese encephalitis, rabies. In the case of travel to countries with endemic diseases that are prevented by live vaccines, a risk assessment of the onset of infection for each patient individually and good information about preventive measures is necessary (9, 10) .
Vaccination in Case of
Preparation of patients with ibc for the application of immunosuppressive therapy
The majority of patients with IBC will be treated with immunosuppressive therapy (80% The results of testing the modality of administration and effect of vaccines in patients with IBC are still not at the highest level (20) . Gastroenterologists who treat patients with IBC best know the current status of each patient. Therefore, they can and should be responsible for deciding when to use the most appropriate immunosuppressive therapy. For the same reasons, they can also assess the response capacity of IBC patients to applied vaccines, or to define clear recommendations for the vaccination of these patients. All this is necessary in order to improve and treat patients with IBC, as this could reduce the prevalence and incidence of infectious complications in these patients, in particular complications that could be prevented by vaccination.
